MedTrace Logo

The Effect of Semaglutide on Cardiovascular Markers and Liver Function

NCT06301191 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 50

Last updated 2024-03-08

No results posted yet for this study

Summary

Fifty patients with diabetes mellitus type 2 and non-alcoholic fatty liver disease (NAFLD) will be enrolled in the study.

25 patients will treated with semaglutide and 25 patients with dipeptidyl peptidase 4 (D-PP4) inhibitors.

At baseline, at four and at 12 months will evaluate the endothelial, cardiovascular and liver function.

Conditions

  • Diabetes Type 2

Interventions

DRUG

Semaglutide, 1.0 mg/mL

Semaglutide, 1.0 mg/mL

DRUG

Dipeptidyl Peptidase 4 inhibitor

Dipeptidyl Peptidase 4 inhibitor

Sponsors & Collaborators

  • Attikon Hospital

    lead OTHER

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-03-01
Primary Completion
2023-03-01
Completion
2024-05-01

Countries

  • Greece

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06301191 on ClinicalTrials.gov